0000950170-24-028307.txt : 20240307
0000950170-24-028307.hdr.sgml : 20240307
20240307201851
ACCESSION NUMBER: 0000950170-24-028307
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240307
DATE AS OF CHANGE: 20240307
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 24732062
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Beskrovnaya Oxana
CENTRAL INDEX KEY: 0001824542
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O DYNE THERAPEUTICS, INC.
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
144
1
primary_doc.xml
144
0001824542
XXXXXXXX
LIVE
0001818794
Dyne Therapeutics, Inc.
001-39509
1560 Trapelo Road
Waltham
MA
02451
(781)-786-8230
Oxana Beskrovnaya
Officer
Common Stock
E*Trade Financial Corporation
3 Edison Drive
Alpharaetta
GA
30005
2373
61344
81958068
03/07/2024
NASDAQ
Common Stock
02/15/2024
Shares acquired upon vesting of restricted stock units granted pursuant to issuer's 2020 stock incentive plan
Issuer
N
2373
02/15/2024
Equity compensation
N
Oxana Beskrovnaya
1560 Trapelo Road
Waltham
MA
02451
Common Stock
12/11/2023
1467
15726
Oxana Beskrovnaya
1560 Trapelo Road
Waltham
MA
02451
Common Stock
01/03/2024
45326
860378
Oxana Beskrovnaya
1560 Trapelo Road
Waltham
MA
02451
Common Stock
01/04/2024
42453
769702
Sale represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023.
03/07/2024
/s/ Richard Scalzo, Attorney-in-Fact